Erasca, Inc.

Erasca, Inc. is a clinical-stage precision oncology company dedicated to the discovery, development, and commercialization of therapies for patients with RAS/MAPK pathway-driven cancers. The company's mission, encapsulated in its name, is "to erase cancer." Headquartered in San Diego, California, Erasca focuses on addressing a critical unmet medical need in oncology. [1, 3, 5, 7, 12, 16, 25, 28, 31, 32, 34, 35, 38]

The company's pipeline is singularly focused on the RAS/MAPK pathway, a signaling cascade implicated in approximately 5.5 million new cancer cases globally each year. Erasca's approach is modality-agnostic, utilizing small molecules, large molecules, and protein degraders to target multiple signaling nodes within this pathway. Key clinical-stage programs include ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. Additionally, the pipeline features ERAS-12, a discovery-stage EGFR D2/D3 biparatopic antibody. [1, 3, 5, 7, 21, 23, 25, 28, 31, 38]

Jonathan E. Lim, M.D., serves as the Chairman, CEO, and Co-founder of Erasca. In April 2026, the company announced positive preliminary Phase 1 dose escalation data for ERAS-0015 in KRAS-mutant solid tumors. However, this news was tempered by a report of a patient death in a clinical trial due to severe side effects, which led to a significant drop in the company's stock price. Erasca has also recently expanded its licensing agreement for ERAS-0015 to secure worldwide rights and completed an upsized public offering in January 2026, bolstering its financial position to fund operations into the second half of 2028. The company is also currently involved in a patent dispute with Revolution Medicines concerning ERAS-0015. [3, 4, 5, 7, 8, 11, 14, 15, 19, 20, 21, 29, 32, 34, 35, 37]